CASPER – The state of Wyoming has received a limited shipment of Remdesivir, the experimental drug that’s shown promise in fighting the novel coronavirus, according to a memo that’s been sent to health care providers across the state.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, or purchase a new subscription.
If you are a current print subscriber, you can set up a free website account and connect your subscription to it by clicking here.
If you are a digital subscriber with an active, online-only subscription then you already have an account here. Just reset your password if you've not yet logged in to your account on this new site.
Otherwise, click here to view your options for subscribing.
Please log in to continue |
CASPER – The state of Wyoming has received a limited shipment of Remdesivir, the experimental drug that’s shown promise in fighting the novel coronavirus, according to a memo that’s been sent to health care providers across the state.
Late last month, the National Institute of Allergy and Infectious Disease announced that preliminary findings indicated that patients who received Remdesivir recovered faster than patients with a placebo.
If those findings hold, then the medication would prove to be the first treatment to improve the outlook for seriously ill coronavirus patients.
The Food and Drug Administration approved the drug earlier this month for emergency use.
But the supply of Remdesivir is limited, and its distribution is being handled by the federal government.
Gilead, the manufacturer of the drug, said in a statement that in January, it only had enough to treat 5,000 patients. That had increased by the end of March to 30,000. The company’s goal, it said, is to have 140,000 treatments ready by the end of May; 500,000 by October; and more than a million by December.